Cardiovascular Systems Stock News

Schonfeld Strategic Advisors LLC bought a new position in Cardiovascular Systems, Inc. (NASDAQ:CSII) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,700 shares of the medical device companys stock, valued at approximately $243,000. Several other hedge funds have also recently modified their holdings of []

Cardiovascular Systems (NASDAQ:CSII) had its target price cut by SVB Leerink from $45.00 to $40.00 in a report issued on Wednesday, Price Targets.com reports. They currently have an outperform rating on the medical device companys stock. SVB Leerink also issued estimates for Cardiovascular Systems Q2 2022 earnings at ($0.09) EPS, Q3 2022 earnings at ($0.04) []

ALTO, CSII, DELL, PRPL, and WRK have been added to the Zacks Rank #5 (Strong Sell) List on November 12, 2021

Cardiovascular Systems' (CSII) coronary franchise registers strong performance globally on continued strength in Japan and Europe.

Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q1 2022 Results - Earnings Call Transcript

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -120.00% and -7.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES FIRST PATIENT TREATED WITH VIPERCROSS™ PERIPHERAL SUPPORT CATHETER

Cardiovascular Systems Inc (NASDAQ: CSII) issued an update on financials citing the COVID-19 impact. The device maker says that the revenue for Q1 FY22 could be negatively affected by more than 10%

The introduction of Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS in Canada will offer physicians an effective treatment option for patients with coronary artery diseases.

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients

Cardiovascular Systems' (CSII) CEO Scott Ward on Q4 2021 Results - Earnings Call Transcript

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients

Shares of Cardiovascular Systems Inc. , a medical device company focused on treatments for vascular and coronary disease, tumbled 10.2% in afternoon trading, and has dropped 18.1% amid a four-day losi

Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.